CONMED Corporation (NYSE: CNMD) today announced financial
results for the fourth quarter and full-year ended December 31,
2022.
Fourth Quarter 2022 Highlights
- Fourth quarter 2022 sales significantly impacted by the
implementation of new warehouse management software.
- Sales of $250.9 million decreased 8.4% year over year as
reported and 7.0% in constant currency. Acquisitions contributed
approximately 460 basis points of growth.
- Domestic revenue decreased 3.9% year over year.
- International revenue decreased 13.8% year over year as
reported and 10.6% in constant currency.
- Diluted net earnings per share (GAAP) were $0.86, an increase
of 14.7% compared to diluted net earnings per share (GAAP) of $0.75
in the fourth quarter of 2021.
- Adjusted diluted net earnings per share(1) were $0.42, a
decrease of 60.7% compared to adjusted diluted net earnings per
share of $1.07 in the fourth quarter of 2021.
Full-Year 2022 Highlights
- Sales of $1,045.5 million increased 3.4% year over year as
reported and 4.6% in constant currency. Acquisitions contributed
approximately 240 basis points of growth.
- Domestic revenue increased 4.8% year over year.
- International revenue increased 1.8% year over year as reported
and 4.3% in constant currency.
- Diluted net loss per share (GAAP) was $2.68, compared to
diluted net earnings per share (GAAP) of $1.94 in 2021.
- Adjusted diluted net earnings per share(1) were $2.65, a
decrease of 17.4% compared to adjusted diluted net earnings per
share of $3.21 in 2021.
- Closed In2Bones transaction on June 13, 2022.
- Closed Biorez transaction on August 9, 2022.
“We are disappointed that our fourth quarter results were
significantly disrupted by the implementation of a new warehouse
management system. We are shipping at or above historical daily
rates, and we continue to work diligently to increase our
efficiency and capacity,” commented Curt R. Hartman, CONMED’s Chair
of the Board, President, and Chief Executive Officer. “I am pleased
with our team’s accomplishments in 2022, including the acquisitions
of In2Bones and Biorez, the closing of our convertible senior notes
offering, and the continued work on new product innovation across
the company. We enter 2023 focused on execution and delivery of
revenue and earnings growth.”
2023 Outlook
The Company expects full-year 2023 reported revenue between
$1.170 billion and $1.220 billion, which includes expected headwind
from foreign exchange between 150 and 200 basis points. Adjusted
diluted net earnings per share(2) is expected to be in the range of
$3.20 to $3.45, which includes expected headwind from foreign
exchange between $0.20 and $0.25.
Supplemental Financial Disclosures
(1) A reconciliation of reported diluted net income (loss) per
share to adjusted diluted net earnings per share, a non-GAAP
financial measure, appears below.
(2) Information reconciling forward-looking adjusted diluted net
earnings per share to the comparable GAAP financial measures is
unavailable to the company without unreasonable effort, as
discussed below.
Conference Call
The Company’s management will host a conference call today at
4:30 p.m. ET to discuss its fourth quarter and full-year 2022
results.
To participate in the conference call via telephone, please
click here to pre-register and obtain the dial-in number and
passcode.
This conference call will also be webcast and can be accessed
from the “Investors” section of CONMED's website at www.conmed.com.
The webcast replay of the call will be available at the same site
approximately one hour after the end of the call.
Consolidated Condensed
Statements of Income (Loss)
(in thousands except per share
amounts, unaudited)
Three Months Ended
Year Ended
December 31,
December 31,
2022
2021
2022
2021
Net sales
$
250,867
$
273,971
$
1,045,472
$
1,010,635
Cost of sales
119,005
118,115
474,227
442,599
Gross profit
131,862
155,856
571,245
568,036
% of sales
52.6
%
56.9
%
54.6
%
56.2
%
Selling & administrative expense
120,737
107,279
454,039
414,754
Research & development expense
12,220
11,361
47,152
43,565
Income (loss) from operations
(1,095
)
37,216
70,054
109,717
% of sales
-0.4
%
13.6
%
6.7
%
10.9
%
Interest expense
9,443
7,569
28,905
35,485
Other expense
-
-
112,011
1,127
Income (loss) before income taxes
(10,538
)
29,647
(70,862
)
73,105
Provision (benefit) for income taxes
(37,122
)
5,203
9,720
10,563
Net income (loss)
$
26,584
$
24,444
$
(80,582
)
$
62,542
Basic EPS
$
0.87
$
0.83
$
(2.68
)
$
2.14
Diluted EPS
0.86
0.75
(2.68
)
1.94
Basic shares
30,484
29,349
30,040
29,162
Diluted shares
30,931
32,769
30,040
32,216
Sales Summary
(in millions, unaudited)
Three Months Ended December
31,
% Change
Domestic
International
2022
2021
As
Reported
Impact
of
Foreign
Currency
Constant
Currency
As
Reported
As
Reported
Impact
of
Foreign
Currency
Constant
Currency
Orthopedic Surgery
$
115.2
$
117.6
-2.0
%
1.7
%
-0.3
%
15.0
%
-11.7
%
2.7
%
-9.0
%
General Surgery
135.7
156.4
-13.2
%
1.2
%
-12.0
%
-11.5
%
-16.9
%
3.8
%
-13.1
%
$
250.9
$
274.0
-8.4
%
1.4
%
-7.0
%
-3.9
%
-13.8
%
3.2
%
-10.6
%
Single-use Products
$
211.9
$
222.8
-4.9
%
1.4
%
-3.5
%
1.1
%
-12.6
%
3.3
%
-9.3
%
Capital Products
39.0
51.2
-23.7
%
1.5
%
-22.2
%
-29.6
%
-18.4
%
2.8
%
-15.6
%
$
250.9
$
274.0
-8.4
%
1.4
%
-7.0
%
-3.9
%
-13.8
%
3.2
%
-10.6
%
Domestic
$
142.8
$
148.6
-3.9
%
0.0
%
-3.9
%
International
108.1
125.4
-13.8
%
3.2
%
-10.6
%
$
250.9
$
274.0
-8.4
%
1.4
%
-7.0
%
Year Ended December
31,
% Change
Domestic
International
2022
2021
As
Reported
Impact
of
Foreign
Currency
Constant
Currency
As
Reported
As
Reported
Impact
of
Foreign
Currency
Constant
Currency
Orthopedic Surgery
$
461.5
$
438.4
5.3
%
1.2
%
6.5
%
9.2
%
3.0
%
2.0
%
5.0
%
General Surgery
584.0
572.2
2.1
%
1.0
%
3.1
%
3.0
%
0.0
%
3.2
%
3.2
%
$
1,045.5
$
1,010.6
3.4
%
1.2
%
4.6
%
4.8
%
1.8
%
2.5
%
4.3
%
Single-use Products
$
874.9
$
820.1
6.7
%
1.1
%
7.8
%
8.3
%
4.5
%
2.6
%
7.1
%
Capital Products
170.6
190.5
-10.5
%
1.1
%
-9.4
%
-13.7
%
-7.6
%
2.0
%
-5.6
%
$
1,045.5
$
1,010.6
3.4
%
1.2
%
4.6
%
4.8
%
1.8
%
2.5
%
4.3
%
Domestic
$
579.0
$
552.5
4.8
%
0.0
%
4.8
%
International
466.5
458.1
1.8
%
2.5
%
4.3
%
$
1,045.5
$
1,010.6
3.4
%
1.2
%
4.6
%
Reconciliation of Reported Net
Income to Adjusted Net Income
(in thousands, except per share
amounts, unaudited)
Three Months Ended December
31, 2022
Gross
Profit
Selling &
Administrative
Expense
Operating
Income
(Loss)
Interest
Expense
Other
Expense
Tax
Expense/
(Benefit)
Effective
Tax Rate
Net
Income
Basic EPS
Adjustments(7)
Diluted
EPS
As reported
$
131,862
$
120,737
$
(1,095
)
$
9,443
$
-
$
(37,122
)
352.3
%
$
26,584
$
-
$
26,584
% of sales
52.6
%
48.1
%
-0.4
%
EPS
$
0.87
$
0.86
Shares
30,484
447
30,931
Acquisition and integration costs(1)
2,096
(3,757
)
5,853
-
-
12,873
(7,020
)
Restructuring and related costs(2)
1,955
(786
)
2,741
-
-
6,029
(3,288
)
Software implementation costs(3)
-
(6,769
)
6,769
-
-
14,889
(8,120
)
Contingent consideration fair value
adjustment(4)
-
(2,518
)
2,518
-
-
5,538
(3,020
)
$
135,913
$
106,907
$
16,786
$
9,443
$
-
$
2,207
$
5,136
Adjusted gross profit %
54.2
%
Amortization(5)
$
1,500
(7,228
)
8,728
(1,506
)
-
2,446
7,788
As adjusted
$
99,679
$
25,514
$
7,937
$
-
$
4,653
26.5
%
$
12,924
$
-
$
12,924
% of sales
39.7
%
10.2
%
Adjusted diluted EPS
$
0.42
Shares
30,484
447
30,931
Convertible note hedges(6)
-
Adjusted diluted shares
30,931
Three Months Ended December
31, 2021
Gross
Profit
Selling &
Administrative
Expense
Operating
Income
Interest
Expense
Other
Expense
Tax
Expense
Effective
Tax Rate
Net
Income
Basic
EPS
Adjustments(7)
Diluted
EPS
As reported
$
155,856
$
107,279
$
37,216
$
7,569
$
-
$
5,203
17.6
%
$
24,444
$
-
$
24,444
% of sales
56.9
%
39.2
%
13.6
%
EPS
$
0.83
$
0.75
Shares
29,349
3,420
32,769
$
155,856
$
107,279
$
37,216
$
7,569
$
-
$
5,203
$
24,444
Adjusted gross profit %
56.9
%
Amortization(5)
$
1,500
(6,811
)
8,311
(3,386
)
-
2,744
8,953
As adjusted
$
100,468
$
45,527
$
4,183
$
-
$
7,947
19.2
%
$
33,397
$
-
$
33,397
% of sales
36.7
%
16.6
%
Adjusted diluted EPS
$
1.07
Shares
29,349
3,420
32,769
Convertible note hedges(6)
(1,446
)
Adjusted diluted shares
31,323
(1) In 2022, the Company incurred inventory step-up adjustments
associated with the acquisition of In2Bones Global, Inc. and
consulting fees, legal fees and other integration related costs
associated with the acquisitions of In2Bones Global, Inc. and
Biorez, Inc. (2) In 2022, the Company incurred consulting fees
related to an operational cost improvement initiative and severance
related to the elimination of certain positions. (3) In 2022, the
Company incurred incremental freight, professional fees and other
costs related to the implementation of a warehouse management
software. (4) In 2022, the Company incurred expense related to the
fair value adjustment of contingent consideration. (5) Includes
amortization of intangible assets, deferred financing fees and debt
discount. (6) Non-GAAP adjusted dilutive weighted average shares
outstanding exclude dilution that is expected to be offset by the
Company’s convertible notes hedge transactions. (7) The Company
adopted ASU 2020-06, effective January 1, 2022. As a result of the
adoption, the Company is required to compute diluted EPS using the
if-converted method. Under the if-converted method, the numerator
is adjusted for interest expense applicable to its convertible
notes (net of tax) and the denominator includes additional common
shares assuming conversion premium and principal portion of the
notes (when permitted or required) are settled in shares.
Subsequent to June 6, 2022, the Company is required to settle the
principal value of its convertible notes in cash.
Reconciliation of Reported Net
Income (Loss) to Adjusted Net Income
(in thousands, except per share
amounts, unaudited)
Year Ended December 31,
2022
Gross
Profit
Selling &
Administrative
Expense
Operating
Income
Interest
Expense
Other
Expense
Tax
Expense/
(Benefit)
Effective
Tax Rate
Net
Income
(Loss)
Basic
EPS
Adjustments (11)
Diluted
EPS
As reported
$
571,245
$
454,039
$
70,054
$
28,905
$
112,011
$
9,720
-13.7
%
$
(80,582
)
$
-
$
(80,582
)
% of sales
54.6
%
43.4
%
6.7
%
EPS
$
(2.68
)
$
(2.68
)
Shares
30,040
-
30,040
Acquisition and integration costs(1)
4,540
(10,063
)
14,603
-
-
46,965
(32,362
)
Legal matters(2)
-
(775
)
775
-
-
(462
)
1,237
Restructuring and related costs(3)
1,955
(786
)
2,741
-
-
6,029
(3,288
)
Software implementation costs(4)
-
(6,769
)
6,769
-
-
14,889
(8,120
)
Contingent consideration fair value
adjustment(5)
-
(2,518
)
2,518
-
-
5,538
(3,020
)
Convertible notes premium on
extinguishment(6)
-
-
-
-
(103,125
)
(61,521
)
164,646
Change in fair value of convertible notes
hedges upon settlement(7)
-
-
-
-
(5,460
)
(3,257
)
8,717
Loss on early extinguishment of
debt(8)
-
-
-
-
(3,426
)
(2,044
)
5,470
$
577,740
$
433,128
$
97,460
$
28,905
$
-
$
15,857
$
52,698
Adjusted gross profit %
55.3
%
Amortization(9)
$
6,000
(27,791
)
33,791
(4,910
)
-
9,381
29,320
As adjusted
$
405,337
$
131,251
$
23,995
$
-
$
25,238
23.5
%
$
82,018
$
2,978
$
84,996
% of sales
38.8
%
12.6
%
Adjusted diluted EPS
$
2.65
Shares
30,040
2,656
32,696
Convertible note hedges(10)
(578
)
Adjusted diluted shares
32,118
Year Ended December 31,
2021
Gross
Profit
Selling &
Administrative
Expense
Operating
Income
Interest
Expense
Other
Expense
Tax
Expense
Effective
Tax Rate
Net
Income
Basic
EPS
Adjustments (11)
Diluted
EPS
As reported
$
568,036
$
414,754
$
109,717
$
35,485
$
1,127
$
10,563
14.4
%
$
62,542
$
-
$
62,542
% of sales
56.2
%
41.0
%
10.9
%
EPS
$
2.14
$
1.94
Shares
29,162
3,054
32,216
Restructuring and related costs (3)
-
(414
)
414
-
-
109
305
Loss on early extinguishment of
debt(8)
-
-
-
-
(1,127
)
281
846
$
568,036
$
414,340
$
110,131
$
35,485
$
-
$
10,953
$
63,693
Adjusted gross profit %
56.2
%
Amortization(9)
$
6,000
(27,133
)
33,133
(13,943
)
-
11,394
35,682
As adjusted
$
387,207
$
143,264
$
21,542
$
-
$
22,347
18.4
%
$
99,375
$
-
$
99,375
% of sales
38.3
%
14.2
%
Adjusted diluted EPS
$
3.21
Shares
29,162
3,054
32,216
Convertible note hedges(10)
(1,273
)
Adjusted diluted shares
30,943
(1) In 2022, the Company incurred inventory step-up adjustments
associated with the acquisition of In2Bones Global, Inc. and
consulting fees, legal fees and other integration related costs
associated with the acquisitions of In2Bones Global, Inc. and
Biorez, Inc. (2) In 2022, the Company incurred costs related to the
settlement of litigation. (3) In 2022, the Company incurred
consulting fees related to an operational cost improvement
initiative and severance related to the elimination of certain
positions. In 2021, the Company incurred restructuring costs
related to restructuring of our sales force. (4) In 2022, the
Company incurred incremental freight, professional fees and other
costs related to the implementation of a warehouse management
software. (5) In 2022, the Company incurred expense related to the
fair value adjustment of contingent consideration. (6) In 2022, the
Company incurred costs related to the conversion premium on the
repurchase and extinguishment of $275.0 million of its 2.625%
Convertible Notes. (7) In 2022, the Company incurred costs related
to the settlement of convertible notes hedge transactions
associated with the repurchase and extinguishment of $275.0 million
of its 2.625% Convertible Notes. (8) In 2022, the Company incurred
costs related to the write-off of deferred financing fees
associated with the repurchase and extinguishment of $275.0 million
of its 2.625% Convertible Notes and term loan paydown. In 2021, the
Company incurred costs related to a loss on early extinguishment
and third-party fees associated with the seventh amended and
restated senior credit agreement. (9) Includes amortization of
intangible assets, deferred financing fees and debt discount. (10)
Non-GAAP adjusted dilutive weighted average shares outstanding
exclude dilution that is expected to be offset by the Company’s
convertible notes hedge transactions. (11) The Company adopted ASU
2020-06, effective January 1, 2022. As a result of the adoption,
the Company is required to compute diluted EPS using the
if-converted method. Under the if-converted method, the numerator
is adjusted for interest expense applicable to its convertible
notes (net of tax) and the denominator includes additional common
shares assuming conversion premium and principal portion of the
notes (when permitted or required) are settled in shares.
Subsequent to June 6, 2022, the Company is required to settle the
principal value of its convertible notes in cash. Adjustments in
2022 are applicable on a non-GAAP basis only since GAAP results are
in a loss position and therefore exclude dilutive potential
shares.
Reconciliation of Reported Net Income (Loss) to EBITDA &
Adjusted EBITDA
(in thousands, unaudited)
Three Months Ended
Year Ended
December 31,
December 31,
2022
2021
2022
2021
Net income (loss)
$
26,584
$
24,444
$
(80,582
)
$
62,542
Provision (benefit) for income taxes
(37,122
)
5,203
9,720
10,563
Interest expense
9,443
7,569
28,905
35,485
Depreciation
4,026
3,975
16,055
16,494
Amortization
13,709
13,502
53,464
54,249
EBITDA
$
16,640
$
54,693
$
27,562
$
179,333
Stock based compensation
5,758
4,332
21,729
16,335
Acquisition and integration costs
5,853
-
14,603
-
Legal matters
-
-
775
-
Restructuring and related costs
2,741
-
2,741
414
Software implementation costs
6,769
-
6,769
-
Contingent consideration fair value
adjustment
2,518
-
2,518
-
Convertible notes premium on
extinguishment
-
-
103,125
-
Change in fair value of convertible notes
hedges upon settlement
-
-
5,460
-
Loss on early extinguishment of debt
-
-
3,426
1,127
Adjusted EBITDA
$
40,279
$
59,025
$
188,708
$
197,209
EBITDA Margin
EBITDA
6.6
%
20.0
%
2.6
%
17.7
%
Adjusted EBITDA
16.1
%
21.5
%
18.1
%
19.5
%
About CONMED Corporation
CONMED is a medical technology company that provides surgical
devices and equipment for minimally invasive procedures. The
Company’s products are used by surgeons and physicians in a variety
of specialties, including orthopedics, general surgery, gynecology,
thoracic surgery, and gastroenterology. For more information, visit
www.conmed.com.
Forward-Looking Statements
This press release and the associated conference call may
contain forward-looking statements based on certain assumptions and
contingencies that involve risks and uncertainties, which could
cause actual results, performance, or trends to differ materially
from those expressed in the forward-looking statements herein or in
previous disclosures. For example, in addition to general industry
and economic conditions, factors that could cause actual results to
differ materially from those in the forward-looking statements may
include, but are not limited to, the risks posed to the Company’s
business, financial condition, and results of operations by the
COVID-19 global pandemic and the various government responses to
the pandemic, including deferral of surgeries, reductions in
hospital and ambulatory surgery center operating volumes,
disruption to potential supply chain reliability; any assumptions
underlying any of the foregoing as well as the risk factors
discussed in the Company's Annual Report on Form 10-K for the full
year ended December 31, 2021, listed under the heading
Forward-Looking Statements in the Company’s most recently filed
Form 10-Q and other risks and uncertainties which may be detailed
from time to time in reports filed by CONMED with the SEC,
including the risks associated with the timing and costs related to
the software implementation as further described in the risk
factors listed in the Current Report filed on Form 8-K on November
15, 2022. Any and all forward-looking statements are made pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995 and relate to the Company’s performance on a
going-forward basis. The Company believes that all forward-looking
statements made by it have a reasonable basis, but there can be no
assurance that management’s expectations, beliefs or projections as
expressed in the forward-looking statements will actually occur or
prove to be correct.
Supplemental Information - Reconciliation of GAAP to Non-GAAP
Financial Measures
The Company supplements the reporting of its financial
information determined under generally accepted accounting
principles in the United States (GAAP) with certain non-GAAP
financial measures, including percentage sales growth in constant
currency; adjusted gross profit; cost of sales excluding specified
items; adjusted selling and administrative expenses; adjusted
operating income; adjusted interest expense; adjusted other
expense; adjusted income tax expense (benefit); adjusted effective
income tax rate; adjusted net income, adjusted diluted shares and
adjusted diluted net earnings per share (EPS). The Company believes
that these non-GAAP measures provide meaningful information to
assist investors and shareholders in understanding its financial
results and assessing its prospects for future performance.
Management believes percentage sales growth in constant currency
and the other adjusted measures described above are important
indicators of its operations because they exclude items that may
not be indicative of, or are unrelated to, its core operating
results and provide a baseline for analyzing trends in the
Company’s underlying business. Further, the presentation of EBITDA
is a non-GAAP measurement that management considers useful for
measuring aspects of the Company’s cash flow. Management uses these
non-GAAP financial measures for reviewing the operating results and
analyzing potential future business trends in connection with its
budget process and bases certain management incentive compensation
on these non-GAAP financial measures.
Net sales on a constant currency basis is a non-GAAP measure.
The Company analyzes net sales on a constant currency basis to
better measure the comparability of results between periods. To
measure percentage sales growth in constant currency, the Company
removes the impact of changes in foreign currency exchange rates
that affect the comparability and trend of net sales. To measure
earnings performance on a consistent and comparable basis, the
Company excludes certain items that affect the comparability of
operating results and the trend of earnings. These adjustments are
irregular in timing, may not be indicative of past and future
performance and are therefore excluded to allow investors to better
understand underlying operating trends.
Because non-GAAP financial measures are not standardized, it may
not be possible to compare these financial measures with other
companies' non-GAAP financial measures having the same or similar
names. These adjusted financial measures should not be considered
in isolation or as a substitute for reported sales growth, gross
profit, cost of sales, selling and administrative expenses,
operating income (loss), interest expense, other expense, income
tax expense (benefit), effective income tax rate, net income
(loss), diluted shares and diluted net earnings (loss) per share,
the most directly comparable GAAP financial measures. These
non-GAAP financial measures are an additional way of viewing
aspects of the Company’s operations that, when viewed with GAAP
results and the reconciliations to corresponding GAAP financial
measures above, provide a more complete understanding of the
business. The Company strongly encourages investors and
shareholders to review its financial statements and publicly filed
reports in their entirety and not to rely on any single financial
measure.
We are unable to present a quantitative reconciliation of our
expected diluted net earnings per share to expected adjusted
diluted net earnings per share as we are unable to predict with
reasonable certainty and without unreasonable effort the impact and
timing of acquisition, integration and other charges. The financial
impact of these items is uncertain and is dependent on various
factors, including timing, and could be material to our
consolidated condensed statements of income (loss).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230202005780/en/
CONMED Corporation Todd W. Garner Chief
Financial Officer 727-214-2975
ToddGarner@conmed.com
CONMED (NYSE:CNMD)
Historical Stock Chart
From Jun 2024 to Jul 2024
CONMED (NYSE:CNMD)
Historical Stock Chart
From Jul 2023 to Jul 2024